Taha Rbab, El-Haddad Hadeel, Almuallim Abdulqader, Alshaiki Fatma, Obaid Elaf, Almoallim Hani
Department of Medicine, Dr Soliman Fakeeh Hospital, Jeddah.
Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Mecca.
Open Access Rheumatol. 2017 Dec 15;9:201-214. doi: 10.2147/OARRR.S149373. eCollection 2017.
Rituximab (RTX) is established for the treatment of rheumatoid arthritis. This systematic review of the literature since 2006 summarizes evidence for the use of RTX in the treatment of additional rheumatological diseases: antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV), hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon. Data from randomized controlled trials are available only for AAV, confirming efficacy for remission induction, including in disease resistant to conventional treatment, and maintenance of remission. Further studies are required to confirm optimal maintenance regimens in AAV, important questions needing to be addressed including protocol administration versus treatment in response to clinical relapse and the importance of maintaining B-cell depletion. Sufficient data are available in other diseases to suggest RTX to be useful and that randomized controlled trials should be conducted.
利妥昔单抗（RTX）已被确立用于治疗类风湿性关节炎。本对2006年以来文献的系统综述总结了RTX用于治疗其他风湿性疾病的证据：抗中性粒细胞胞浆抗体相关性血管炎（AAV）、丙型肝炎病毒相关冷球蛋白血症性血管炎、过敏性紫癜、强直性脊柱炎和雷诺现象。仅AAV有随机对照试验数据，证实其在诱导缓解（包括对传统治疗耐药的疾病）及维持缓解方面的疗效。需要进一步研究以确认AAV的最佳维持方案，需要解决的重要问题包括方案给药与根据临床复发进行治疗以及维持B细胞耗竭的重要性。其他疾病有足够数据表明RTX有用，应开展随机对照试验。
